News
Harvard Quietly Resolves Anti-Palestinian Discrimination Complaint With Ed. Department
News
Following Dining Hall Crowds, Harvard College Won’t Say Whether It Tracked Wintersession Move-Ins
News
Harvard Outsources Program to Identify Descendants of Those Enslaved by University Affiliates, Lays Off Internal Staff
News
Harvard Medical School Cancels Class Session With Gazan Patients, Calling It One-Sided
News
Garber Privately Tells Faculty That Harvard Must Rethink Messaging After GOP Victory
Vaccine
A bacterial pneumonia vaccine approved by the Food and Drug Administration on Monday "will have limited application in this community because the incidence of bacterial pneumonia here is very low," Dr. Sholem Postel, acting director of University Health Services, said yesterday.
The F.D.A. cleared Pneumovax for market early next year. The vaccine has proven in tests to be about 80 per cent effective.
"Large-scale mass immunization will not be recommended, however, and the vaccine will be used for certain restricted groups such as the elderly in nursing homes," Postel said yesterday.
"It is important to note that most types of pneumonia, which is the nation's fifth leading killer, are non-bacterial," Postel added.
Want to keep up with breaking news? Subscribe to our email newsletter.